Building MOMENTUM for Patients with Myelofibrosis

We are a clinical stage drug development company focused on the registration and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis.

Learn More

MOMENTUM Clinical Trial for Patients with Myelofibrosis

The MOMENTUM Clinical Trial is a randomized, double-blind, Phase 3 clinical trial designed to enroll 180 myelofibrosis patients who are symptomatic and anemic, and who have been treated previously with a JAK inhibitor.